AgomAb Therapeutics (NASDAQ:AGMB) Director Purchases 15,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein purchased 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were bought at an average price of $6.90 per share, with a total value of $103,500.00. Following the completion of the acquisition, the director owned 40,000 shares of the company’s stock, valued at $276,000. This trade represents a 60.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

AgomAb Therapeutics Stock Up 1.8%

Shares of AGMB opened at $6.97 on Friday. The company’s 50 day moving average price is $10.38 and its 200 day moving average price is $11.88. AgomAb Therapeutics NV has a 52 week low of $6.46 and a 52 week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, equities research analysts anticipate that AgomAb Therapeutics NV will post -1.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on AGMB. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. Piper Sandler initiated coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, AgomAb Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.